ArticleBiomaterials2013
Engineered multilayer ovarian tissue that secretes sex steroids and peptide hormones in response to gonadotropins.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 54 citations in OpenAlex.
- Using Organoids to Unlock the Potential of Human Torpor for Spaceflight.Current stem cell reports · 2026Article
- Bioengineering Ovarian Endocrine Function: From Follicle Modeling to Cell-Based Hormone Therapy.Advanced healthcare materials · 2026Review
- Cell assays in microcompartments driven by droplet microfluidics and hydrogel technologies.Journal of biochemistry · 2026Review
- Immune Roles of Canonically Non-Immune Cells in Biomaterials Response.Cell biomaterials · 2026Article
- Engineering ovarian tissue via biofabrication and 3D bioprinting: Challenges and emerging perspectives.Bioengineering & translational medicine · 2026Review
- Biomaterials for Reproductive Restoration: Translating Engineering Innovations.Biomaterials research · 2026Review
- Infertility treatment using polysaccharides-based hydrogels: new strategies in tissue engineering and regenerative medicine.Journal of nanobiotechnology · 2025Review
- Multi-cellular engineered living systems to assess reproductive toxicology.Reproductive toxicology (Elmsford, N.Y.) · 2024Review
- A Simple Mathematical Model Demonstrates the Potential for Cell-Based Hormone Therapy to Address Dysregulation of the Hypothalamus-Pituitary-Ovary Axis in Females with Loss of Ovarian Function.Annals of biomedical engineering · 2024Article
- Injectable Biomimetic Hydrogel Constructs for Cell-Based Menopausal Hormone Therapy with Reduced Breast Cancer Potential.Biomaterials research · 2024Article
- New Solutions for Old Problems: How Reproductive Tissue Engineering Has Been Revolutionizing Reproductive Medicine.Annals of biomedical engineering · 2023Review
- Design and Application Strategies of Natural Polymer Biomaterials in Artificial Ovaries.Annals of biomedical engineering · 2023Review
- Roadmap on biomaterials for women's health.JPhys materials · 2023Article
- Organoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies.Frontiers in immunology · 2022Review
- A framework for developing sex-specific engineered heart models.Nature reviews. Materials · 2022Review
- Female Oncofertility: Current Understandings, Therapeutic Approaches, Controversies, and Future Perspectives.Journal of clinical medicine · 2021Review
- Regenerative Medicine Approaches in Bioengineering Female Reproductive Tissues.Reproductive sciences (Thousand Oaks, Calif.) · 2021Review
- Engineering Functional Rat Ovarian Spheroids Using Granulosa and Theca Cells.Reproductive sciences (Thousand Oaks, Calif.) · 2021Article
- Hormone autocrination by vascularized hydrogel delivery of ovary spheroids to rescue ovarian dysfunctions.Science advances · 2021Article
- Creating an Artificial 3-Dimensional Ovarian Follicle Culture System Using a Microfluidic System.Micromachines · 2021Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Although hormone replacement therapy is an option for the loss of ovarian function, hormone delivery through pharmacological means results in various clinical complications. The present study was designed to deliver sex steroids by a functional construct fabricated using encapsulation techniques. Theca and granulosa cells isolated from ovaries of 21-day old rats were encapsulated in multilayer alginate microcapsules to recapitulate the native follicular structure. Cells encapsulated in two other schemes were used as controls to assess the importance of the multilayer structure. The endocrine functions of the encapsulated cells were assessed in vitro for a period of 30 days. Encapsulated cells showed sustained viability during long-term in vitro culture with those encapsulated in multilayer capsules secreting significantly higher and sustained concentrations of 17 β-estradiol (E(2)) than the two other encapsulation schemes (p < 0.05, n = 6) in response to follicle-stimulating hormone (FSH) and luteinizing hormone (LH). In addition, cells in the multilayer microcapsules also secreted activin and inhibin in vitro. In contrast, when granulosa and theca cells were cultured in 2D culture, progesterone (P(4)) secretion increased while E(2) secretion decreased over a 30-day period. In summary, we have designed a multilayer engineered ovarian tissue that secretes sex steroids and peptide hormones and responds to gonadotropins, thus demonstrating the ability to recapitulate native ovarian structure ex vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.